announced development of a vaccine candidate, codenamed NVX-CoV2373, to establish immunity to SARS-CoV-2. Novavax's work is in competition for vaccine development...

company redirected its efforts to focus on development and approval of its NVX-CoV2373 vaccine for COVID-19. The COVID-19 vaccine Nuvaxovid was approved in...

also reached an agreement with Novavax for the production of Novavax's NVX-CoV2373 (Covovax) vaccine for India and other low and middle-income countries...

rolling review of NVX-CoV2373, a COVID‑19 vaccine being developed by Novavax CZ AS (a subsidiary of Novavax, Inc.) and a rolling review of CVnCoV, a COVID‑19...

SARS-CoV-2 recombinant spike protein nanoparticle with adjuvant $1.6 billion for advance commercial-scale manufacturing July 7, 2020 NVX‑CoV2373 Funding...

First Approval of the Protein-Based Adjuvanted Nuvaxovid (NVX-CoV2373) Novavax Vaccine for SARS-CoV-2 Could Increase Vaccine Uptake and Provide Immune Protection...

memorandum of understanding with Novavax to pursue manufacturing its NVX-CoV2373 vaccine at the Biologics Manufacturing Centre. In September 2020, President...

Australia's first human trials of a candidate COVID-19 vaccine was Novavax's NVX-CoV2373 which began in Melbourne by 26 May 2020. In a February 2021 pre-budget...

an emergency use listing (EUL) for NVX-CoV2373, expanding the basket of WHO-validated vaccines against the SARS-CoV-2 virus. World Health Organization...

Australia's first human trials of a candidate COVID-19 vaccine, Novavax's NVX-CoV2373, began in Melbourne. On 6 June, both New South Wales and Victoria reported...